Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova's sales experienced a remarkable growth of 29%, reaching $803 million in 2024, with management projecting revenues in the range of $940 to $955 million for the upcoming year. The company's strategic focus on cardiopulmonary solutions and neuromodulation devices positions it favorably within the healthcare market, with an impressive reliance on the U.S. market, which constitutes approximately half of its total revenue. Additionally, projections for the aura6000 device indicate a potential increase in market share, contributing to anticipated sales growth from $30 million in 2027 to $70 million by 2029, further underscoring the company's positive growth trajectory.

Bears say

LivaNova faces a potential slowdown in revenue growth, with expectations of low-single-digit increases primarily due to ongoing challenges in its Neuromodulation and Cardiovascular segments. The company is also experiencing operating margin contraction and is projected to report earnings below consensus estimates, further contributing to a bearish outlook. Additionally, there are significant risks associated with the approval of new products and growth expectations in its core markets, which may further hinder financial performance.

Livanova (LIVN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 7 analysts, Livanova (LIVN) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.